Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has been assigned an average broker rating score of 1.75 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and two have given a strong buy recommendation to the company.

Brokerages have set a 1-year consensus target price of $31.25 for the company, according to Zacks. Zacks has also given Rhythm Pharmaceuticals an industry rank of 103 out of 265 based on the ratings given to related companies.

A number of brokerages have recently commented on RYTM. Cowen reaffirmed a “buy” rating and set a $40.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Morgan Stanley began coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They set an “equal weight” rating and a $23.00 target price on the stock. Finally, Bank of America began coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $30.00 target price on the stock.

In other Rhythm Pharmaceuticals news, Director David P. Meeker acquired 25,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $425,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James E. Flynn acquired 355,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,035,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 1,285,000 shares of company stock worth $21,845,000.

Shares of Rhythm Pharmaceuticals (NASDAQ RYTM) opened at $27.81 on Thursday. Rhythm Pharmaceuticals has a 1 year low of $21.38 and a 1 year high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($1.38). research analysts predict that Rhythm Pharmaceuticals will post -1.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals, Inc. (RYTM)” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/30/brokerages-set-31-25-target-price-for-rhythm-pharmaceuticals-inc-rytm.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.